As many biological products face losing their patents in the next decade, the pharmaceutical industry needs an abbreviated regulatory pathway for approval of biosimilar drug products, which are cost-effective, follow-on/subsequent versions of the innovator”s biologic products. But scientific challenges remain due to the complexity of both the manuf
Beli ebook ini dan dapatkan 1 lagi PERCUMA!
Format PDF ● Halaman-halaman 444 ● ISBN 9781466579705 ● Penerbit CRC Press ● Diterbitkan 2013 ● Muat turun 6 kali ● Mata wang EUR ● ID 2715426 ● Salin perlindungan Adobe DRM
Memerlukan pembaca ebook yang mampu DRM